Lipoxygenase Inhibitors [Pharmacological Action]
Tree Number(s): D016859
MeSH Unique ID: D016859
- benoxaprofen (Supplementary Concept)
- phenidone (Supplementary Concept)
- nafazatrom (Supplementary Concept)
- azelastine (Supplementary Concept)
- 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid (Supplementary Concept)
- piriprost (Supplementary Concept)
- 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (Supplementary Concept)
- 9-hydroperoxy-11,12-octadecadienoic acid (Supplementary Concept)
- alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol (Supplementary Concept)
- 4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one (Supplementary Concept)
- Wy 45911 (Supplementary Concept)
- N-(3-phenoxycinnamyl)acetohydroxamic acid (Supplementary Concept)
- 5-hexyloxy-3',4'-dihydroxy-6,7-dimethoxyflavone 4'-phosphate (Supplementary Concept)
- MK-886 (Supplementary Concept)
- LY 178002 (Supplementary Concept)
- oxphaman (Supplementary Concept)
- zileuton (Supplementary Concept)
- 3-(5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiazol-2-yl)propanol (Supplementary Concept)
- S(alpha)-methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid (Supplementary Concept)
- N-hydroxy-N-(1-(4-(phenylmethoxy)phenyl)ethyl)-acetamide (Supplementary Concept)
- L 670630 (Supplementary Concept)
- N-linoleoyldopamine (Supplementary Concept)
- chebulagic acid (Supplementary Concept)
- 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid (Supplementary Concept)
- camelliaside C (Supplementary Concept)
- 2',5'-dimethoxy-3,4-dihydroxychalcone (Supplementary Concept)
- licofelone (Supplementary Concept)
- N-hydroxy-N-(1-(2-phenyl-5-benzofuranyl)ethyl)furancarboxamide (Supplementary Concept)
- 5-(N-hydroxy-N-(1-(2-(3,4,5-trimethoxyphenyl)-5-benzofuranyl)ethyl)amino)-5-oxopentanoate (Supplementary Concept)
- N-hydroxy-N-(1-(2-phenylbenzofuran-5-yl)ethyl)urea (Supplementary Concept)
- atreleuton (Supplementary Concept)
- 1-phenylperhydro-1,2,4-triazin-3-one (Supplementary Concept)
- L 708780 (Supplementary Concept)
- CMI 392 (Supplementary Concept)
- 4-(2-oxapentadeca-4-yne)phenylpropanoic acid (Supplementary Concept)
- ((E)-(5)-(3,5-di-tert-butyl-4-hydroxybenzylidene)- 2-ethyl-1,2-isothiazolidine-1,1-dioxide) (Supplementary Concept)
- ocobullenone (Supplementary Concept)
- 3-oxo-tirucall-8,24-dien-21-oic acid (Supplementary Concept)
- 1,6-dimethyl-2-(4'-N-n-propylsuccinamido)methyl-3-hydroxypyridin-4(1H)-one (Supplementary Concept)
- N-4-(4-methoxyphenylaminosulfonyl)benzoisoselenothiazolidone (Supplementary Concept)
- N-4-(4-fluorophenylaminosulfonyl)benzoisoselenothiazolidone (Supplementary Concept)
- 4-(5-fluoro-3-(4-(2-methyl-1H-imidazol-1-yl)benzyloxy)phenyl)-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide (Supplementary Concept)
- 4-(5-fluoro-3-(4-(2-methyl-1H-imidazol-1-yl)benzyloxy)phenyl)-4-methoxy-3,4,5,6-tetrahydro-2H-pyran (Supplementary Concept)
- tetrapetalone B (Supplementary Concept)
- tetrapetalone C (Supplementary Concept)
- tetrapetalone D (Supplementary Concept)
- S 29606 (Supplementary Concept)
- S 30621 (Supplementary Concept)
- 5-Loxin (Supplementary Concept)
- 12-labdene-15,16,(8)17-trial (Supplementary Concept)
- 2-(4-hydroxyphenyl)-3-(3,5-dihydroxyphenyl)propenoic acid (Supplementary Concept)
- 2-(4-aminophenyl)-3-(3,5-dihydroxylphenyl)propenoic acid (Supplementary Concept)
- LQFM-091 (Supplementary Concept)
- Diethylcarbamazine (MeSH Term)
- Masoprocol (MeSH Term)
- 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine (MeSH Term)